RGEN Stock Overview
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$171.28 |
| 52 Week High | US$211.13 |
| 52 Week Low | US$110.45 |
| Beta | 1.01 |
| 1 Month Change | -7.36% |
| 3 Month Change | -7.67% |
| 1 Year Change | 15.23% |
| 3 Year Change | -22.05% |
| 5 Year Change | 160.22% |
| Change since IPO | 1,571.02% |
Recent News & Updates
Recent updates
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?
Dec 28Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Repligen: Now Best Biotech Nearby Cap-Gain Prospect
Sep 27Repligen partners with DRS daylight solutions
Sep 19When Should You Buy Repligen Corporation (NASDAQ:RGEN)?
Sep 19Do Repligen's (NASDAQ:RGEN) Earnings Warrant Your Attention?
Aug 23Repligen briefly turns positive after report of rejected takeover offer
Aug 11Calculating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Aug 08Shareholder Returns
| RGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.4% | 4.5% | 1.2% |
| 1Y | 15.2% | 5.2% | 24.7% |
Return vs Industry: RGEN exceeded the US Life Sciences industry which returned 5.2% over the past year.
Return vs Market: RGEN underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| RGEN volatility | |
|---|---|
| RGEN Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: RGEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 1,783 | Tony Hunt | www.repligen.com |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
Repligen Corporation Fundamentals Summary
| RGEN fundamental statistics | |
|---|---|
| Market cap | US$9.56b |
| Earnings (TTM) | US$41.58m |
| Revenue (TTM) | US$638.76m |
230.0x
P/E Ratio15.0x
P/S RatioIs RGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGEN income statement (TTM) | |
|---|---|
| Revenue | US$638.76m |
| Cost of Revenue | US$323.54m |
| Gross Profit | US$315.23m |
| Other Expenses | US$273.65m |
| Earnings | US$41.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 0.74 |
| Gross Margin | 49.35% |
| Net Profit Margin | 6.51% |
| Debt/Equity Ratio | 29.4% |
How did RGEN perform over the long term?
See historical performance and comparison